A review article: Sevelamer hydrochloride and metabolic acidosis in dialysis patients

Yoshinari Oka, Masashi Miyazaki, Shigeko Takatsu, Toshiaki Ohara, Keisuke Toda, Futoshi Uno, Hiroaki Matsuda

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Sevelamer hydrochloride is a phosphate binder and its effectiveness to reduce the cardiovascular mortality of dialysis patients has been tested. Sevelamer hydrochloride also contains chlorine, so a decrease in bicarbonate due to chlorine load was anticipated and metabolic acidosis thought to associate with sevelamer hydrochloride has been reported in some papers. We reported that sevelamer hydrochloride exacerbated metabolic acidosis in hemodialysis patients, depending on the dosage. Also a Japanese nationwide survey suggested that sevelamer hydrochloride usage potentially aggravates acidosis in dialysis patients. A multi-institute research study by Edmung et al. has shown that metabolic acidosis, with serum CO2 below 17.5 mmol/L, is by itself associated with increased risk of death in dialysis patients. Furthermore, the Dialysis Outcomes and Practice Patterns Study (DOPPS) revealed that both high (> 27 mmol/L) and low (<or = 17 mmol/L) serum bicarbonate (total CO2) levels were associated with increased risk for mortality and hospitalization. There has not been any significant evidence to show that sevelamer hydrochloride has reduced the cardiovascular mortality of dialysis patients compared with calcium-based binder. Clinicians should check not only the level of chlorine but also the level of total CO2 or bicarbonate during the treatment with sevelamer hydrochloride, and control metabolic acidosis.

Original languageEnglish
Pages (from-to)283-286
Number of pages4
JournalCardiovascular and Hematological Disorders - Drug Targets
Volume8
Issue number4
DOIs
Publication statusPublished - 2008

Fingerprint

Acidosis
Dialysis
Chlorine
Bicarbonates
Mortality
Sevelamer
Serum
Renal Dialysis
Hospitalization
Phosphates
Calcium

Keywords

  • Bicarbonate
  • Dialysis
  • Dose depending
  • Metabolic acidosis
  • Prognosis
  • Sevelamer hydrochloride

ASJC Scopus subject areas

  • Molecular Medicine
  • Cardiology and Cardiovascular Medicine
  • Hematology
  • Pharmacology

Cite this

A review article : Sevelamer hydrochloride and metabolic acidosis in dialysis patients. / Oka, Yoshinari; Miyazaki, Masashi; Takatsu, Shigeko; Ohara, Toshiaki; Toda, Keisuke; Uno, Futoshi; Matsuda, Hiroaki.

In: Cardiovascular and Hematological Disorders - Drug Targets, Vol. 8, No. 4, 2008, p. 283-286.

Research output: Contribution to journalArticle

Oka, Yoshinari ; Miyazaki, Masashi ; Takatsu, Shigeko ; Ohara, Toshiaki ; Toda, Keisuke ; Uno, Futoshi ; Matsuda, Hiroaki. / A review article : Sevelamer hydrochloride and metabolic acidosis in dialysis patients. In: Cardiovascular and Hematological Disorders - Drug Targets. 2008 ; Vol. 8, No. 4. pp. 283-286.
@article{639242fdf6064a5d8f014675e7d7a336,
title = "A review article: Sevelamer hydrochloride and metabolic acidosis in dialysis patients",
abstract = "Sevelamer hydrochloride is a phosphate binder and its effectiveness to reduce the cardiovascular mortality of dialysis patients has been tested. Sevelamer hydrochloride also contains chlorine, so a decrease in bicarbonate due to chlorine load was anticipated and metabolic acidosis thought to associate with sevelamer hydrochloride has been reported in some papers. We reported that sevelamer hydrochloride exacerbated metabolic acidosis in hemodialysis patients, depending on the dosage. Also a Japanese nationwide survey suggested that sevelamer hydrochloride usage potentially aggravates acidosis in dialysis patients. A multi-institute research study by Edmung et al. has shown that metabolic acidosis, with serum CO2 below 17.5 mmol/L, is by itself associated with increased risk of death in dialysis patients. Furthermore, the Dialysis Outcomes and Practice Patterns Study (DOPPS) revealed that both high (> 27 mmol/L) and low (",
keywords = "Bicarbonate, Dialysis, Dose depending, Metabolic acidosis, Prognosis, Sevelamer hydrochloride",
author = "Yoshinari Oka and Masashi Miyazaki and Shigeko Takatsu and Toshiaki Ohara and Keisuke Toda and Futoshi Uno and Hiroaki Matsuda",
year = "2008",
doi = "10.2174/187152908786786197",
language = "English",
volume = "8",
pages = "283--286",
journal = "Cardiovascular and Hematological Disorders - Drug Targets",
issn = "1871-529X",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - A review article

T2 - Sevelamer hydrochloride and metabolic acidosis in dialysis patients

AU - Oka, Yoshinari

AU - Miyazaki, Masashi

AU - Takatsu, Shigeko

AU - Ohara, Toshiaki

AU - Toda, Keisuke

AU - Uno, Futoshi

AU - Matsuda, Hiroaki

PY - 2008

Y1 - 2008

N2 - Sevelamer hydrochloride is a phosphate binder and its effectiveness to reduce the cardiovascular mortality of dialysis patients has been tested. Sevelamer hydrochloride also contains chlorine, so a decrease in bicarbonate due to chlorine load was anticipated and metabolic acidosis thought to associate with sevelamer hydrochloride has been reported in some papers. We reported that sevelamer hydrochloride exacerbated metabolic acidosis in hemodialysis patients, depending on the dosage. Also a Japanese nationwide survey suggested that sevelamer hydrochloride usage potentially aggravates acidosis in dialysis patients. A multi-institute research study by Edmung et al. has shown that metabolic acidosis, with serum CO2 below 17.5 mmol/L, is by itself associated with increased risk of death in dialysis patients. Furthermore, the Dialysis Outcomes and Practice Patterns Study (DOPPS) revealed that both high (> 27 mmol/L) and low (

AB - Sevelamer hydrochloride is a phosphate binder and its effectiveness to reduce the cardiovascular mortality of dialysis patients has been tested. Sevelamer hydrochloride also contains chlorine, so a decrease in bicarbonate due to chlorine load was anticipated and metabolic acidosis thought to associate with sevelamer hydrochloride has been reported in some papers. We reported that sevelamer hydrochloride exacerbated metabolic acidosis in hemodialysis patients, depending on the dosage. Also a Japanese nationwide survey suggested that sevelamer hydrochloride usage potentially aggravates acidosis in dialysis patients. A multi-institute research study by Edmung et al. has shown that metabolic acidosis, with serum CO2 below 17.5 mmol/L, is by itself associated with increased risk of death in dialysis patients. Furthermore, the Dialysis Outcomes and Practice Patterns Study (DOPPS) revealed that both high (> 27 mmol/L) and low (

KW - Bicarbonate

KW - Dialysis

KW - Dose depending

KW - Metabolic acidosis

KW - Prognosis

KW - Sevelamer hydrochloride

UR - http://www.scopus.com/inward/record.url?scp=60549096467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60549096467&partnerID=8YFLogxK

U2 - 10.2174/187152908786786197

DO - 10.2174/187152908786786197

M3 - Article

C2 - 19075639

AN - SCOPUS:60549096467

VL - 8

SP - 283

EP - 286

JO - Cardiovascular and Hematological Disorders - Drug Targets

JF - Cardiovascular and Hematological Disorders - Drug Targets

SN - 1871-529X

IS - 4

ER -